SEARCH

PTAB.US: Decisions of PTAB Patent Trial and Appeal Board Updated Daily.

Tuesday, December 17, 2013

cyclobenzaprine, boehringer

custom search

REVERSED
Tech Center 1600 Biotechnology and Organic Chemistry
1636 Ex Parte Claret 11874838 - (D) JENKS 112(1) Parker Highlander PLLC QIAN, CELINE X

Tech Center 2400 Networking, Multiplexing, Cable, and Security
2452 Ex Parte Darago et al 10609325 - (D) BUI 103 OGILVIE LAW FIRM HOANG, HIEU T

Tech Center 2800 Semiconductors, Electrical and Optical Systems and Components
2872 Ex Parte Blyth et al 10565094 - (D) TIMM 103 SALIWANCHIK, LLOYD & EISENSCHENK CHWASZ, JADE R

2899 Ex Parte Hwang et al 11170486 - (D) GARRIS 102(b)/103 H.C. PARK & ASSOCIATES, PLC MONTALVO, EVA Y

Tech Center 3600 Transportation, Construction, Electronic Commerce, Agriculture, National Security, and License & Review
3624 Ex Parte Johnson 10500179 - (D) MEDLOCK 103 BROOKS KUSHMAN P.C. SANTIAGO, LUIS F

3657 Ex Parte Beri 10595350 - (D) SCANLON 102(b)/103 BROOKS KUSHMAN P.C. BURCH, MELODY M

3672 Ex Parte In T Hout 11572464 - (D) GERSTENBLITH 103 Foley & Lardner LLP KRECK, JOHN J

AFFIRMED-IN-PART 
Tech Center 1700 Chemical & Materials Engineering
1755 Ex Parte Mershin et al 11639372 - (D) MURPHY 103 103 ELMORE PATENT LAW GROUP, PC TRINH, THANH TRUC

See In re Cyclobenzaprine Hydrochloride, 676 F. 3d 1063, 1081 (Fed. Cir. 2012)

Evidence that others tried but failed to develop a claimed invention may carry significant weight in an obviousness inquiry. "While absolute certainty is not necessary to establish a reasonable expectation of success, there can be little better evidence negating an expectation of success than actual reports of failure." Boehringer Ingelheim Vetmedica, Inc. v. Schering-Plough Corp., 320 F.3d 1339, 1354 (Fed. Cir.2003).

HARMON 6: 84, 347
DONNER 8: 1073; 10: 910-18

Tech Center 2100 Computer Architecture and Software
2172 Ex Parte Borovsky 11294790 - (D) MILLS 102(b) 102(b)/103 Wolfe-SBMC ELL, MATTHEW

Tech Center 2400 Networking, Multiplexing, Cable, and Security
2468 Ex Parte Erickson et al 12779489 - (D) BUSCH 102(b) 102(b)/103 MOSER TABOADA / VONAGE HOLDINGS CORP. JAGANNATHAN, MELANIE

Tech Center 2800 Semiconductors, Electrical and Optical Systems and Components
2897 Ex Parte Clevenger et al 12206314 - (D) FRANKLIN 103 102(b)/103 Ryan, Mason & Lewis, LLP TOLEDO, FERNANDO L

AFFIRMED 
Tech Center 1700 Chemical & Materials Engineering
1716 Ex Parte Smith et al 11245758 - (D) PER CURIAM 103 PATTERSON & SHERIDAN, LLP - - APPM/TX ZERVIGON, RUDY

Tech Center 2400 Networking, Multiplexing, Cable, and Security
2432 Ex Parte Sprosts et al 11635921 - (D) COURTENAY 112(1)/103 HICKMAN PALERMO TRUONG BECKER BINGHAM WONG LLP LANIER,BENJAMIN E

2442 Ex Parte Campbell 11656770 - (D) HUME 103 HEWLETT-PACKARD COMPANY SURVILLO, OLEG

2456 Ex Parte Kim et al 11787425 - (D) KRIVAK 102(b) THE FARRELL LAW FIRM, P.C. CHANG, TOM Y

Tech Center 2600 Communications
2645 Ex Parte SUNG et al 11939172 - (D) COURTENAY 102(b)/103 THE FARRELL LAW FIRM, P.C. MAPA, MICHAEL Y

2671 Ex Parte Condon et al 11135677 - (D) BONILLA 103 DUFT BORNSEN & FETTIG, LLP DEMETER, HILINA K

2687 Ex Parte Tomasson et al 11620208 - (D) STRAUSS 103 BROOKS KUSHMAN P.C./FGTL TUN, NAY L

Tech Center 2800 Semiconductors, Electrical and Optical Systems and Components
2885 Ex Parte Jeon 11473747 - (D) GAUDETTE 103 BGL BANNAN, JULIE A

Tech Center 3700 Mechanical Engineering, Manufacturing, and Products & Design
3754 Ex Parte Schmelter et al 12285584 - (D) GERSTENBLITH 103 WALTER OTTESEN HOOK, JAMES F

REEXAMINATION

AFFIRMED
3307 Ex parte SEIKO EPSON CORPORATION 90011817 5,158,377 07/620,411 KOHUT 103 STROOCK & STROOCK & LAVAN LLP For Third Party Requester: Glory South Software Manufacturing Inc. Alston & Bird LLP RALIS, STEPHEN J original WIECKING, DAVID

FEDERAL CIRCUIT

AFFIRMED
Tech Center 2600 Communications
2623 2624 COGNEX CORPORATION AND COGNEX TECHNOLOGY & INVESTMENT CORPORATION, Appellants, v. INTERNATIONAL TRADE COMMISSION, Appellee, AND MVTEC SOFTWARE GMBH AND MVTEC, LLC, Intervenors. 2011-1098 7,016,539 09/114,335 7,065,262 10/705,563 LINN noninfringement Proskauer Rose LLP; United States International Trade Commission; Foley & Lardner, LLP KIM, CHONG R; MARIAM, DANIEL G

AFFIRMED
Tech Center 2100 Computer Architecture and Software
2155 MOTOROLA MOBILITY, LLC (formerly known as Motorola Mobility, Inc.), Appellant, v. INTERNATIONAL TRADE COMMISSION, Appellee, AND MICROSOFT CORPORATION, Intervenor. 2012-1535 6,370,566 09/058,679 RADER asserted claims valid and domestic industry requirement satisfied Quinn Emanuel Urquhart & Sullivan, LLP; United States International Trade Commission; Sidley Austin, LLP TRAN, PHILIP B

1 comment :

Dominant Testo said...

However, in the same cyclobenzaprine cannot be considered as the first class of treatment. However, within the equal cyclobenzaprine dosage high can not be considered as the first elegance of remedy. Is applied collectively with relaxation and physical answer for control skeletal muscle occasions, as an instance, torment or harm. cyclobenzaprine high will likewise be utilized for purposes not ordered in this pharmaceutical guide.You need to now not utilize cyclobenzaprine at the off threat which you have a thyroid pain, coronary heart rectangular, congestive coronary heart sadness, a heart musicality disorder, or you have got these days proven a few kindness assault.Do at no time in the future make use of #cyclobenzaprine if you have taken a MAO inhibitor within the previous 14 days. Cyclobenzaprine, the mainstream kingdom of the logo call capsules Flexeril and Amrix, is a muscle relaxer that assuages throb and uneasiness coming about due to strains, side effects for Cyclobenzaprine sprains, and other muscle mischances.